

ANDA 217517

ANDA APPROVAL

Teva Pharmaceuticals, Inc.
400 Interpace Parkway, Building A
Morris Corporate Center III
Parsippany, NJ 07054
Attention: Bernard Domnic
Director, Regulatory Affairs

Dear Bernard Domnic:

This letter is in reference to your abbreviated new drug application (ANDA) received for review on July 8, 2022, submitted pursuant to section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for Pazopanib Tablets, 200 mg.

Reference is also made to the tentative approval letter issued by this office on July 31, 2023, and to any amendments thereafter.

We have completed the review of this ANDA and have concluded that adequate information has been presented to demonstrate that the drug meets the requirements for approval under the FD&C Act. Accordingly the ANDA is **approved**, effective on the date of this letter. We have determined your Pazopanib Tablets, 200 mg, to be bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Votrient Tablets, 200 mg, of Novartis Pharmaceuticals Corporation.

Reference is also made to FDA's Competitive Generic Therapy Designation – Grant letter dated August 31, 2022.

We note that Teva Pharmaceuticals, Inc. was granted a Competitive Generic Therapy (CGT) designation for Pazopanib Tablets, 200 mg. However, as noted in the August 31, 2022, CGT Designation – Grant Letter, your drug product is not eligible for CGT exclusivity under section 505(j)(5)(B)(v) of the FD&C Act because there were unexpired patents or exclusivities listed in FDA's *Approved Drug Products with Therapeutic Equivalence Evaluations* (Orange Book) for the RLD at the time of submission of your ANDA.

Please note that if FDA requires a Risk Evaluation and Mitigation Strategy (REMS) for a listed drug, an ANDA referencing that listed drug also will be required to have a REMS. See section 505-1(i) of the FD&C Act.

COMPENDIAL STANDARDS

A drug with a name recognized in the official United States Pharmacopeia or official National Formulary (USP-NF) generally must comply with the compendial standard for strength, quality, and purity, unless the difference in strength, quality, or purity is plainly stated on its label (see FD&C Act § 501(b), 21 USC 351(b)). FDA typically cannot share application-specific information contained in submitted regulatory filings with third parties, which includes USP-NF. To help ensure that a drug continues to comply with compendial standards, application holders may work directly with USP-NF to revise official USP monographs. More information on the USP-NF is available on USP's website at https://www.uspnf.com/.

REQUIREMENTS AND RECOMMENDATIONS POST APPROVAL

Under applicable statutes, regulations, and guidances, your ANDA may be subject to certain requirements and recommendations post approval, including requirements regarding changes to approved ANDAs, postmarketing reporting, promotional materials, and annual facility fees, among others. For information on post-approval requirements and recommendations for ANDAs and a list of resources for ANDA holders, we refer you to https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/requirements-and-resources-approved-andas.

Sincerely yours,

{See appended electronic signature page}

For Edward M. Sherwood Director Office of Regulatory Operations Office of Generic Drugs Center for Drug Evaluation and Research



Digitally signed by Catherine Poole

Date: 10/19/2023 08:40:22AM

GUID: 5407887a000a1c0c26055eafb8e3258a